Early Response to Bortezomib Combined Chemotherapy Can Help Predict Survival in Patients with Multiple Myeloma Who Are Ineligible for Stem Cell Transplantation
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Ho Sup | - |
dc.contributor.author | Kim, Yang Soo | - |
dc.contributor.author | Kim, Kihyun | - |
dc.contributor.author | Kim, Jin Seok | - |
dc.contributor.author | Kim, Hyo Jung | - |
dc.contributor.author | Min, Chang-Ki | - |
dc.contributor.author | Suh, Cheolwon | - |
dc.contributor.author | Eom, Hyeon-Seok | - |
dc.contributor.author | Yoon, Sung-Soo | - |
dc.contributor.author | Lee, Jae Hoon | - |
dc.contributor.author | Kim, Min Kyong | - |
dc.contributor.author | Kim, Sung-Hyun | - |
dc.contributor.author | Bae, Sung Hwa | - |
dc.contributor.author | Mun, Yeung-Chul | - |
dc.contributor.author | Jo, Deog Yeon | - |
dc.contributor.author | Chung, Joo-Seop | - |
dc.date.available | 2020-02-29T00:46:20Z | - |
dc.date.created | 2020-02-06 | - |
dc.date.issued | 2013-01 | - |
dc.identifier.issn | 1011-8934 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/14846 | - |
dc.description.abstract | Novel agents to treat multiple myeloma (MM) have increased complete respone (CR) rates compared with conventional chemotherapy, and the quality of the response to treatment has been correlated with survival. The purpose of our study was to show how of early response to bortezomib combined chemotherapy influences survival in patients with newly diagnosed MM who are ineligible for stem cell transplantation. We assessed patient responses to at least four cycles of bortezomib using the International Myeloma Working Group response criteria. The endpoints were comparisons of progression free survival (PFS) and overall survival (OS) between early good response group (A group) and poor response group (B group). We retrospectively analyzed data from 129 patients registered by the Korean Multiple Myeloma Working Party, a nationwide registration of MM patients. The 3 yr PFS for the A and B groups was 55.6% and 18.4%, respectively (P < 0.001). The 3 yr OS for the A and B groups was 65.3% and 52.9%, respectively (P = 0.078). The early response to at least four cycle of bortezomib before next chemotherapy may help predict PFS in patients with MM who are ineligible stem cell transplantation. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | KOREAN ACAD MEDICAL SCIENCES | - |
dc.relation.isPartOf | JOURNAL OF KOREAN MEDICAL SCIENCE | - |
dc.subject | PREDNISONE PLUS THALIDOMIDE | - |
dc.subject | HIGH-DOSE CHEMOTHERAPY | - |
dc.subject | ELDERLY-PATIENTS | - |
dc.subject | MELPHALAN-PREDNISONE | - |
dc.subject | PATIENTS OLDER | - |
dc.subject | DEXAMETHASONE | - |
dc.subject | THERAPY | - |
dc.subject | DOXORUBICIN | - |
dc.subject | TRIAL | - |
dc.subject | VINCRISTINE | - |
dc.title | Early Response to Bortezomib Combined Chemotherapy Can Help Predict Survival in Patients with Multiple Myeloma Who Are Ineligible for Stem Cell Transplantation | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000314527100012 | - |
dc.identifier.doi | 10.3346/jkms.2013.28.1.80 | - |
dc.identifier.bibliographicCitation | JOURNAL OF KOREAN MEDICAL SCIENCE, v.28, no.1, pp.80 - 86 | - |
dc.identifier.kciid | ART001737198 | - |
dc.identifier.scopusid | 2-s2.0-84874778308 | - |
dc.citation.endPage | 86 | - |
dc.citation.startPage | 80 | - |
dc.citation.title | JOURNAL OF KOREAN MEDICAL SCIENCE | - |
dc.citation.volume | 28 | - |
dc.citation.number | 1 | - |
dc.contributor.affiliatedAuthor | Lee, Jae Hoon | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | Early Response | - |
dc.subject.keywordAuthor | Multiple Myeloma | - |
dc.subject.keywordAuthor | Bortezomib | - |
dc.subject.keywordAuthor | Survival | - |
dc.subject.keywordPlus | PREDNISONE PLUS THALIDOMIDE | - |
dc.subject.keywordPlus | HIGH-DOSE CHEMOTHERAPY | - |
dc.subject.keywordPlus | ELDERLY-PATIENTS | - |
dc.subject.keywordPlus | MELPHALAN-PREDNISONE | - |
dc.subject.keywordPlus | PATIENTS OLDER | - |
dc.subject.keywordPlus | DEXAMETHASONE | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | DOXORUBICIN | - |
dc.subject.keywordPlus | TRIAL | - |
dc.subject.keywordPlus | VINCRISTINE | - |
dc.relation.journalResearchArea | General & Internal Medicine | - |
dc.relation.journalWebOfScienceCategory | Medicine, General & Internal | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.